AKTX Stock Analysis: Buy, Sell, or Hold?
AKTX - Akari Therapeutics plc ADR (0.01 USD)
$10.76
-1.03 (-8.78%)
▼
5d:
-17.27%
30d:
-41.13%
90d:
+7721.82%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When AKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AKTX is down 17.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AKTX is down 17.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKTX is currently trading at $10.76, which is considered fair relative to its 30-day fair value range of $8.41 to $17.47.
Technical Outlook: Technically, AKTX is in a strong uptrend. The price is currently testing key support at $10.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.78 (+127.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKTX is in a strong uptrend. The price is currently testing key support at $10.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.78 (+127.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.41 -
$17.47
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.8%)
- BULLISH: Trading 127.1% below Wall St target ($26.78)
- WARNING: Recommendation downgraded due to -17.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.41 -
$17.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.55
Resistance Level
$15.90
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.04
Wall Street Target
$26.78
(+127.1%)
Share & Embed Analysis
Last updated: June 24, 2026 4:09 PM ET
Data refreshes hourly during market hours. Next update: 5:09 PM
Data refreshes hourly during market hours. Next update: 5:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 58 HOLD |
